Modulation of ROS/NO production by murine peritoneal macrophages in response to bacterial CpG DNA stimulation

Experimental Oncology

Volumn 28, Issue 2, 2006, Pages 114-120

  Olishevsky, S ^a   Burlaka, A ^a   Sidorik, E ^a   Shlyakhovenko, V ^a   Garpenko, Yu ^a   Kozak, V ^a  

^a R E KAVETSKY INSTITUTE OF EXPERIMENTAL PATHOLOGY   (Ukraine)

Author keywords

Bacillus subtilis; CpG DNA; Electron paramagnetic resonance; Nitric oxide; Peritoneal macrophages; ROS; Superoxide anion

Indexed keywords

BACTERIAL DNA; INDUCIBLE NITRIC OXIDE SYNTHASE; NITRIC OXIDE; PERITONEAL DIALYSIS FLUID; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACILLUS SUBTILIS; CANCER TRANSPLANTATION; CONTROLLED STUDY; CPG ISLAND; DNA ISOLATION; DRUG EFFECT; EHRLICH ASCITES TUMOR; ELECTRON SPIN RESONANCE; ENZYME ACTIVITY; IN VITRO STUDY; METABOLIC ACTIVATION; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; SPIN TRAPPING;

ANIMALS; BACILLUS SUBTILIS; CARCINOMA, EHRLICH TUMOR; CPG ISLANDS; DNA, BACTERIAL; ELECTRON SPIN RESONANCE SPECTROSCOPY; MACROPHAGE ACTIVATION; MACROPHAGES, PERITONEAL; MICE; MICE, INBRED BALB C; NADPH OXIDASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; REACTIVE OXYGEN SPECIES; SINGLET OXYGEN;

EID: 33746538927     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Auger MJ. Mononuclear phagocytes. Recent research suggests a large repertoire of actions. Br Med J 1989; 298: 546-8.
2. Keller RR, Keist A, Wechsler A, Leist TP, Van der Meid PH. Mechanisms of macrophage-mediated tumor cell killing: a comparative analysis of the roles of reactive nitrogen intermediates and tumor necrosis factor. Int J Cancer 1990; 46: 682-6.
3. Duffie GP, Young MRI. Tumoricidal activity of alveolar and peritoneal macrophages of C57BL/6 mice bearing metastatic variants of Lewis lung carcinoma. J Leukocyte Biol 1991; 49: 8-14.
4. Vadiveloo PK. Macrophages: proliferation, activation, and cell cycle proteins. J Leukocyte Biol 1999; 66: 579-82.
5. Robinson JP. Oxygen and nitrogen reactive metabolites and phagocytic cells. In: Phagocyte Function: A Guide for Research and Clinical Evaluation. J.P. Robinson, G.F. Babcock, eds. Wiley-Liss Inc., 1998. 217-52.
6. Berezhnaya NM, Chekhun VF. Immunology of tumor growth. Kiev: Naukova dumka, 2005; 790p (in Russian).
7. Nathan C, Shiloh MU. Reactive oxygen and nitrogen intermediates in the relationship between mammalian hosts and microbial pathogens. Proc Natl Acad Sci USA 2000; 97, 8841-8.
8. DiNiapoli MR, Calderon CL, Lopez DM. The altered tumorocidal capacity of macrophages isolated from tumor-bearing mice is related to reduced expression of the inducible nitric oxide synthase gene. J Exp Med 1996; 183: 1323-9.
9. Adams D, Hamilton T. The cell biology of macrophage activation. Ann Rev Immunol 1984; 2: 283-318.
10. Pace JL, Russel SW. Activation of mouse macrophages for tumor cell killing. I. Quantitative analysis of the interactions between lymphokines and lypopolysaccharide. J Immunol 1981; 126: 1863-7.
11. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Ann Rev Immunol 2002; 20: 709-60.
12. Shlyakhovenko VA, Olishevsky SV, Kozak VV, Vanish YV, Rybalko SL. Anticancer and immunostimulatory effects of nucleoprotein fraction of Bacillus subtilis 7025 culture medium filtrate. Exp Oncol 2003; 25: 119-23.
13. Klinman DM. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nature Rev Immunol 2004; 4: 1-10.
14. Hacker G, Redecke V, Häcker H. Activation of the immune system by bacterial CpG-DNA. Immunology 2002; 105: 245-51.
15. Stacey KJ, Sweet MJ, Hume DA. Macrophages ingest and are activated by bacterial DNA. J Immunol 1996; 157: 2116-22.
16. Yi AK, Tuetken R, Redford T, Waldschmidt M, Kirsch J, Krieg A. CpG motifs in bacterial DNA activate leukocytes through the pH-dependent generation of reactive oxygen species. J Immunol 1998; 160: 4755-61.
17. Sweet MJ, Stacey KJ, Kakuda DK, Markovich D, Hume DA. IFN-γ primes macrophage responses to bacterial DNA. J Interferon Cytokine Res 1998; 18: 263-71.
18. Carpentier AF, Auf G, Delattre J-Y. CpG-oligonucleotides for cancer immunotherapy: review of the literature and potential applications in malignant glioma. Frontiers Biosci 2003; 8: 115-27.
19. Olishevsky SV, Kozak W, Vanish W, Shlyakhovenko VA. Immunostimmulatory CpG DNA in cancer vaccinotherapy. Exp Oncol 2003; 25: 83-92.
20. Olishevsky S, Kozak V, Vanish Yu, Potebuya G, Lisovenko G, Olexienko I, Mazur O, Rybalko S, Shlyakhovenko V. Characteristics of extracellular DNA containing unmethylated CpG motifs isolated from Bacillus subtilis culture medium filtrate. Exp Oncol 2004; 26: 265-70.
21. The nucleic acids protocols handbook. R. Rapley, ed. Humana Press, 2000; 1072 p.
22. + T cells: implications for tumor immunotherapy. Immunity 1996; 4: 555-564.
23. nd edition, 1998; 115 p.
24. Lai C-S, Komarov AM. Spin trapping of nitric oxide produced in vivo in septic-shock mice. FEBS Letters 1994; 345: 120-4.
25. Buettner GR, Mason RP. Spin-trapping methods for detecting superoxide and hydroxyl free radicals in vitro and in vivo. In: Critical reviews of oxidative stress and aging advances in basic science, diagnostics and intervention. Cutler RG, Rodriguez H, eds. World Scientific, New Jersey, London, Singapore, Hong Kong. V.I., 2003, Chapter 2, pp. 27-38.
26. Burlaka AP, Danko MY, Sydoryk YP. Kinetic patterns of generation rate and content of oxide radicals in endoplasmic reticulum membranes upon chemical carcinogenesis of liver and mammary glands. Reports Nat Acad Sci Ukr 1994; 10: 141-5.
27. Olishevsky S, Shlyakhovenko V, Kozak V, Yanish Y. Response of different organs of immune system of mice upon administration bacterial CpG DNA. Exp Oncol 2005; 27: 290-7.
28. Adachi T, Mano H, Shinochara T. Tumorocidal effects of human macrophage-colony-stimulating factor against human ovarian carcinoma bearing mice and its therapeutic effect when combined with cisplatin. Cancer Immunol Immunother 1993; 37: 1-6.
29. Fjumara A, Belfiore A, Russo G, Salomone E, Santonocito GM, Ippolito O, Vigneri R, Gangemi P. In situ evidence of neoplastic cell phagocytosis by macrophages in papillary thyroid cancer. J Clin Endocrinol Metab 1997; 82: 1615-20.
30. Baskić D, Aćimović L, Samardźić G, Durdević P, Dukić A, Arsenijević NN. The altered activation state of macrophages isolated from ascetic fluid of patients with peritoneal carcinomatosis. Arch Oncol 2000; 8: 99-103.
31. 2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs. J Nat Cancer Inst 2004; 96: 1171-80.
32. Dima VF, Ionescu MD, Balotescu C, Dima SV, Vasiliu V, Lacky D. New approach to the adoptive immunotherapy of Walker-256 carcinosarcoma with activated macrophages combined with photodynamic therapy. Roum Arch Microbiol Immunol 2001; 60: 237-56.
33. Chen GG, Lau WY, Lai PB, Chun YS, Chak EC, Leung BC, Lam IK, Lee JF, Chui AK. Activation of Kupffer cells inhibits tumor growth in a murine model system. Int J Cancer 2002; 99: 713-20.
34. Thiounn N, Pages F, Mejean A, Descotes JL, Fridman WH, Romet-Lemonne JL. Adoptive immunotherapy for superficial bladder cancer with autologous macrophage activated killer cells. J Urol 2002; 168: 2373-6.
35. Fan D, Liaw A, Denkins YM, Collins JH, Arsdall MV, Chang JL, Chakrabarty S, Nguyen D, Kruzel E, Fidler IJ. Type-1 transforming growth factor-beta differentially modulates tumoricidal activity of murine peritoneal macrophages against metastatic variants of the B16 murine melanoma. J Exp Ther Oncol 2002; 2: 286-97.
36. Chen GG, Chak EC, Chun YS, Lam IK, Sin FL, Leung BC, Ng HK, Poon WS. Glioma apoptosis induced by macrophages involves both death receptor-dependent and independent pathways. J Lab Clin Med 2003; 141: 190-9.
37. Bonnette B, Larmonier N, Favre N, Fromentin A, Moutet M, Martin M, Gurbuxani S, Solary E, Chauffert B, Martin F. Identification of tumor-infiltrating macrophages as the killers of tumor cells after immunization in a rat model system. J Immunol 2001; 167: 5077-83.
38. Pages F, Lebel-Binay S, Vieillefond A, Deneux L, Cambillau M, Soubrane O, Debre B, Tardy D, Lemonne JL, Abastado JP, Fridman WH, Thiounn N. Local immunostimulation induced by intravesical administration of autologous interferon-gamma-activated macrophages in patients with superficial bladder cancer. Clin Exp Immunol 2002; 127: 303-9.
39. Tsung K, Dolan JP, Tsung YL, Norton JA. Macrophages as effector cells in interleukin 12-induced T cell-dependent tumor rejection. Cancer Res 2002; 62: 5069-75.
40. Du C, Feng N, Jin H, Lee V, Wang M, Wright JA, Young AH. Macrophages play a critical role in the anti-tumor activity of Virulizin®. Int J Oncol 2003; 23: 1341-6.
41. Adams DO, Hall T, Steplewski Z, Koprowski H. Tumors undergoing rejection induced by monoclonal antibodies of the IgG2a isotype contain increased numbers of macrophages activated for a distinctive form of antibody-dependent cytolysis. Proc Natl Acad Sci USA 1984; 81: 3506-10.
42. Shetye J, Frodin JE, Christensson B, Grant C, Jacobsson B, Sundelius S. Immunohistochemical monitoring of metastatic colorectal carcinoma in patients treated with monoclonal antibodies (Mad 17-1A). Cancer Immunol Immunother 1988; 27: 154-62.
43. Sotomayor EM, Fu YX, Lopez-Cepero M, Herbert L, Jimenez JJ, Albrracin C, Lopez DM. Role of tumor derived cytokines on the immune system of mice bearing a mammary adenocarcinoma. J Immunol 1991; 147: 2816-23.
44. Alleva DG, Burger CJ, Elgert KD. Tumor-induced regulation of suppressor macrophage nitric oxide and TNF-alpha production. Role of tumor derived IL-10, TGF-beta and PGE2. J Immunol 1994; 153: 1674-86.
45. Auf G, Carpentier AF, Chen L, Le Clanche C, Delattre J-Y. Implication of macrophages in tumor rejection induced by CpG-oligodeoxynucleotides without antigen. Clin Cancer Res 2001; 7: 3540-3.
46. Guzik TJ, Korbut R, Adamek-Guzik T. Nitric oxide and superoxide in inflammation and immune regulation. J Physiol Pharmacol 2003; 54: 469-87.